A 2/1 Sunitinib Dosing Schedule Provides Superior Antitumor Effectiveness and Less Toxicity Than a 4/2 Schedule for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis

Background: The standard sunitinib schedule to treat metastatic renal cell carcinoma (mRCC) is 4 weeks on/2 weeks off (4/2). However, some studies revealed intolerable adverse events (AEs) in patients on this schedule. An alternative schedule, 2 weeks on/1 week off (2/1), may overcome this issue. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Huan, Li, Meng, Wu, Qian, Wang, Li, Hong, Zhengdong, Yi, Fengming, Wei, Yiping, Zhang, Wenxiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7069552/
https://www.ncbi.nlm.nih.gov/pubmed/32211333
http://dx.doi.org/10.3389/fonc.2020.00313

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7069552/
https://www.ncbi.nlm.nih.gov/pubmed/32211333
http://dx.doi.org/10.3389/fonc.2020.00313

Ejemplares similares